I-Mab
NASDAQ:IMAB
I-Mab
NASDAQ:IMAB
Price:
3.98
USD
0.51%
Market Closed
Market Cap:
$325m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
11.4
Current
233%
More Expensive
vs 3-y average of 3.4
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
P/B
=
11.4
Market Cap
/
$325m
Total Equity
¥197m
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
P/B
=
11.4
Market Cap
/
$325m
Total Equity
¥197m
Valuation Scenarios
I-Mab is trading
above
its 3-year average
If P/B returns to its 3-Year Average (3.4), the stock would be worth $1.2 (70% downside from current price).
Statistics
Positive Scenarios
0/4
Maximum Downside
-78%
Maximum Upside
No Upside Scenarios
Average Downside
69%
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.4 | $3.98 |
0%
|
| 3-Year Average | 3.4 | $1.2 |
-70%
|
| 5-Year Average | 3.9 | $1.36 |
-66%
|
| Industry Average | 4.2 | $1.46 |
-63%
|
| Country Average | 2.4 | $0.86 |
-78%
|
Forward P/B
Today’s price vs future total equity
Not enough data available to calculate forward P/B
Peer Comparison
All Countries
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
I-Mab
NASDAQ:IMAB
|
325m USD | 11.4 | -59.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | -107.4 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 21.4 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 7.1 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 5.9 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 2.5 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 6.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 2.3 | 31.1 |
P/B Multiple
P/E Multiple
Market Distribution
Higher than 94% of
companies
in
China
Percentile
94rd
Based on 7 605 companies
94rd percentile
11.4
Low
0 — 1.5
Typical Range
1.5 — 3.9
High
3.9
—
∞
Distribution Statistics
China
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.4 |
| 70th Percentile | 3.9 |
| Max | 1 172 445.9 |
Other Multiples
I-Mab
Glance View
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.
IMAB
Intrinsic Value
Not Available
